OCS
- Oculis Holding AG
()
Overview
Company Summary
Oculis Holding AG (OCS) is a company that operates in the pharmaceutical and biotechnology industry. The company specializes in developing ophthalmic treatments and therapies for various eye conditions and diseases.
Oculis focuses on utilizing innovative technologies and drug delivery systems to enhance the effectiveness and convenience of eye care. Their main area of expertise is in developing topical, non-invasive treatments that can be administered directly to the eye surface.
One of Oculis' distinctive capabilities is their proprietary formulation technology, known as Solubilizing Nanoparticle Platform (SNP). This technology enables the effective solubilization and delivery of drugs to the target area of the eye, improving the therapeutic outcomes and patient experience.
The company's product pipeline includes treatments for diseases such as diabetic macular edema, uveitis, dry eye disease, allergic conjunctivitis, and glaucoma, among others. Oculis aims to address unmet medical needs in the ophthalmic field and provide better treatment options for patients suffering from these conditions.
To further develop and commercialize their products, Oculis collaborates with pharmaceutical companies, research institutions, and healthcare organizations. By leveraging their expertise in drug delivery and ophthalmology, Oculis seeks to bring innovative and effective therapies to the market, improving the quality of life for individuals with eye-related disorders.